Gilead Sciences, Inc. vs AbbVie Inc.
A head-to-head of Gilead Sciences, Inc. (GILD) and AbbVie Inc. (ABBV) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | GILD | ABBV |
|---|---|---|
| Market Cap | $160.15B | $355.43B |
| P/E (TTM) | 17.57 | 106.96 |
| Forward P/E | 14.02 | 13.41 |
| P/S | 5.61 | 5.66 |
| P/B | 6.84 | -57.26 |
| EV/EBITDA | 12.15 | 24.76 |
| Dividend Yield | 2.52% | 2.95% |
| Profit Margin | 30.99% | 5.79% |
| Gross Margin | 78.83% | 70.24% |
| Operating Margin | 39.74% | 32.85% |
| Revenue Growth (YoY) | +4.39% | +12.43% |
| FCF Yield | 6.13% | 5.62% |
| Debt / Equity | 94.64 | — |
| Current Ratio | 1.97 | 0.80 |
Share:
Compare Gilead Sciences, Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.